BLINCYTO
Google image searchProduct monograph
Active ingredient
blinatumomab, 38.5 MCG/VIAL
DIN: 02450283
Dosage form(s): POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Description: LYOPHILIZED POWDER. FOR I.V. INFUSION.
Schedule: Prescription / Schedule D
Company: AMGEN CANADA INC
Date: 17-MAR-2016
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FX — Other monoclonal antibodies and antibody drug conjugates (ATC, ATC/DDD)
- L01FX07 — BLINATUMOMAB (ATC/DDD)
